研究发现,排泄物和氧气战略并未改善心脏外科病人的治疗结果。 Study finds exenatide and oxygen strategies did not improve outcomes for heart surgery patients.
GLORIOUS 试验发现，GLP-1 受体激动剂艾塞那肽并不能改善心脏手术患者的死亡、中风或器官衰竭等结局。 The GLORIOUS trial found that exenatide, a GLP-1 receptor agonist, did not improve outcomes like death, stroke, or organ failure in heart surgery patients. 这项涉及约1 400名病人的研究也显示,自由或限制性的氧气化战略没有带来任何好处。 The study, involving about 1,400 patients, also showed no benefit from a liberal or restrictive oxygenation strategy. 尽管取得了这些中性结果,研究人员仍强调需要进一步研究,以找到更好的方法,改善心脏外科期间和之后的患者结果。 Despite these neutral results, researchers highlighted the need for further studies to find better methods for improving patient outcomes during and after heart surgery.